Technavio has announced their latest pipeline analysis report on the Fabry disease market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Fabry disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180623005070/en/
Technavio has published a new report on the drug development pipeline for Fabry disease, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Fabry disease: Market overview
Fabry disease is a lipid-metabolism disorder or lysosomal storage disorder, is a rare genetic disease, which is inherited in an X-linked pattern. This disorder can lead to a deficiency of alpha-galactosidase A enzyme. Alpha-galactosidase A breaks glycolipids ( a combination of sugar and lipid molecules).
According to a senior analyst at Technavio for infectious and rare diseases, “In a few glycolipid molecules such as globotriaosylceramide (GL-3 or Gb3), lyso-GL-3/Gb3, and related glycolipids. The alpha-galactosidase A enzyme removes the terminal galactose sugar from the end of these glycolipid molecules.”
Fabry disease segmentation
This market research report segments the fabry disease market based on therapies employed that includes monotherapy, combination therapy, and unknown, RoA (IV, oral, and unknown), therapeutic modalities (small molecules, biological, gene therapy, and unknown), targets for drugs under development (alpha-galactosidase, alpha-galactosidase A, glucosylceramide synthase, BET, and unknown), drugs under development (pre-clinical, phase I, phase I/II, phase II, phase III, and pre-registration), MoA (alpha-galactosidase replacement, alpha-galactosidase stimulator, glucosylceramide synthase inhibitor, alpha-galactosidase A inhibitor, BET inhibitor, gene transference, and unknown), and recruitment status (recruiting, completed, active not recruiting, not yet recruiting, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
- Recruitment volume
Key Companies
- Type of players
- Company Overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180623005070/en/
Contacts:
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com
